Advanced non-invasive imaging biomarker for use in drug trials

In healthcare, timely and personalised interventions have a crucial role in the ultimate effectiveness of both current and future treatments for a wide range of diseases. Rapid correct diagnosis is key in unlocking personalised approaches for degenerative diseases such as dementia and other neurodegenerative conditions, where stratification is mandatory for correct treatment. Early detection of these diseases would result in a significantly improved patient prognosis but there is a dearth of diagnostic options in these indications. AINOSTICS' technology represents a breakthrough that would provide an automated, extensible, and personalised healthcare platform for assisting the clinical diagnosis of tissue modifying diseases using multi-modal imaging and non-imaging MRI data; useful for both the treatment of patients, and importantly, in the development of novel therapeutics.

AINOSTICS' technology can automatically and intelligently analyse scans to provide sensitive and accurate micro-structural information about key tissue and organ structures then compare this with information from healthy populations to detect the signatures of disease. We intend for AINOSTICS' software to become a routine part of clinical practice and drug development as the results of our intelligent analysis will provide clinicians, researchers, and imaging centres a convenient and cost-effective means to get reliable, quantitative and objective diagnostic data.

For serious global diseases, AINOSTICS' technology has the potential to save time during patient assessments, accelerate clinical pathways, standardise the quality of care and improve patient outcomes in addition to making important contributions to the development of disease modifying therapeutics.